Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials

被引:29
作者
Addario, Bonnie [1 ]
Geissler, Jan [2 ]
Horn, Marcia K. [3 ]
Krebs, Linda U. [4 ]
Maskens, Deborah [5 ]
Oliver, Kathy [6 ]
Plate, Ananda [7 ]
Schwartz, Erin [8 ]
Willmarth, Nicole [9 ]
机构
[1] GO2 Fdn Lung Canc, San Carlos, CA USA
[2] Patvocates, Riemerling, Germany
[3] Int Canc Advocacy Network, Phoenix, AZ USA
[4] Int Soc Nurses Canc Care, Vancouver, BC, Canada
[5] Int Kidney Canc Coalit, Guelph, ON, Canada
[6] Int Brain Tumour Alliance, Tadworth, England
[7] Myeloma Patients Europe, Brussels, Belgium
[8] Max Fdn, Seattle, WA USA
[9] Amer Brain Tumor Assoc, Chicago, IL USA
关键词
cancer; clinical decision making; patient advocacy; patient-reported outcomes; DECISION-MAKING; PRO; EXPERIENCE; PERSPECTIVES; ASSESSMENTS; FRAMEWORK; SOCIETY; LIVES; CARE;
D O I
10.1111/hex.12997
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context Patient-reported outcomes (PROs) are used in parallel with clinical evidence to inform decisions made by industry, clinicians, regulators, health technology assessment bodies and other health-care decision-makers. In addition, PRO data can also guide shared decision making and individual patient choice. Yet, the quality of many PROs in cancer clinical trials is suboptimal and requires improvement to add value to health care and policy decision making. Objective To show how the integration of the patient and/or patient advocate at all stages of PRO development can help to realize the full potential of PROs. Methods We examined the literature to show that the patient voice is often absent from the planning and implementation of PROs in cancer clinical trials. Good practice examples from the literature were combined with guideline recommendations, training or educational resources, and our own experience to create detailed practical steps for the inclusion of patients and/or patient advocates throughout PRO development. Results Patient or patient advocates can play an active role in shaping PROs that are meaningful to the patient. They can contribute to content, choice of medium and implementation in a way that may support PRO completion and minimize missing data. Patients and their advocates can work to ensure PRO findings are disseminated appropriately in a way that is accessible to patients. Conclusion This practical guidance aims to optimize PRO development and implementation in clinical trials, resulting in robust, relevant data that reflect the patient experience and that support decisions made by all stakeholders involved in research and health care.
引用
收藏
页码:41 / 51
页数:11
相关论文
共 63 条
[1]   Patient value: Perspectives from the advocacy community [J].
Addario, Bonnie J. ;
Fadich, Ana ;
Fox, Jesme ;
Krebs, Linda ;
Maskens, Deborah ;
Oliver, Kathy ;
Schwartz, Erin ;
Spurrier-Bernard, Gilliosa ;
Turnham, Timothy .
HEALTH EXPECTATIONS, 2018, 21 (01) :57-63
[2]   The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative [J].
Alonso, Jordi ;
Bartlett, Susan J. ;
Rose, Matthias ;
Aaronson, Neil K. ;
Chaplin, John E. ;
Efficace, Fabio ;
Leplege, Alain ;
Lu, Aiping ;
Tulsky, David S. ;
Raat, Hein ;
Ravens-Sieberer, Ulrike ;
Revicki, Dennis ;
Terwee, Caroline B. ;
Valderas, Jose M. ;
Cella, David ;
Forrest, Christopher B. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11
[3]  
[Anonymous], Research Report, V1364
[4]   Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting [J].
Atkinson, Thomas M. ;
Rogak, Lauren J. ;
Heon, Narre ;
Ryan, Sean J. ;
Shaw, Mary ;
Stark, Liora P. ;
Bennett, Antonia V. ;
Basch, Ethan ;
Li, Yuelin .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (04) :735-743
[5]  
Au HJ, 2010, EXPERT REV PHARM OUT, V10, P119, DOI [10.1586/erp.10.15, 10.1586/ERP.10.15]
[6]  
Au T, 2018, ASCO PALL SUPP CAR O
[7]  
Basch E, 2013, NEW ENGL J MED, V369, P5
[8]   Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial [J].
Basch, Ethan ;
Pugh, Stephanie L. ;
Dueck, Amylou C. ;
Mitchell, Sandra A. ;
Berk, Lawrence ;
Fogh, Shannon ;
Rogak, Lauren J. ;
Gatewood, Marcha ;
Reeve, Bryce B. ;
Mendoza, Tito R. ;
O'Mara, Ann M. ;
Denicoff, Andrea M. ;
Minasian, Lori M. ;
Bennett, Antonia V. ;
Setser, Ann ;
Schrag, Deborah ;
Roof, Kevin ;
Moore, Joan K. ;
Gergel, Thomas ;
Stephans, Kevin ;
Rimner, Andreas ;
DeNittis, Albert ;
Bruner, Deborah Watkins .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02) :409-418
[9]   Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].
Basch, Ethan ;
Reeve, Bryce B. ;
Mitchell, Sandra A. ;
Clauser, Steven B. ;
Minasian, Lori M. ;
Dueck, Amylou C. ;
Mendoza, Tito R. ;
Hay, Jennifer ;
Atkinson, Thomas M. ;
Abernethy, Amy P. ;
Bruner, Deborah W. ;
Cleeland, Charles S. ;
Sloan, Jeff A. ;
Chilukuri, Ram ;
Baumgartner, Paul ;
Denicoff, Andrea ;
St Germain, Diane ;
O'Mara, Ann M. ;
Chen, Alice ;
Kelaghan, Joseph ;
Bennett, Antonia V. ;
Sit, Laura ;
Rogak, Lauren ;
Barz, Allison ;
Paul, Diane B. ;
Schrag, Deborah .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09)
[10]   The Missing Voice of Patients in Drug-Safety Reporting [J].
Basch, Ethan .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869